SCILEX HOLDING COMPANY - COMMON STOCK

Scilex Holding Company Announces Closing of $10 Million Bought Deal Offering

05 مارس 2024 16:01:00 بحسب Nasdaq GlobeNewswire

Scilex Holding Company Sets Launch Price of $595 per 150ml bottle of Gloperba®, its First and Only Liquid Oral Version of the Anti-Gout Medicine Colchicine Indicated for the Prophylaxis of Painful Gout Flares in Adults; Expected Plans to Launch in the First Half of 2024

05 مارس 2024 09:00:00 بحسب Nasdaq GlobeNewswire

Scilex Holding Company Launches New Website to Showcase Growing Portfolio of Non-Opioid Products and Pipeline Information Updates

04 مارس 2024 09:00:00 بحسب Nasdaq GlobeNewswire

Scilex Holding Company Announces that the Official Committee of Unsecured Creditors of Sorrento Therapeutics, Inc., has Filed a Motion with the U.S. Bankruptcy Court to Extend the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend from March 31, 2024 to September 30, 2024

02 مارس 2024 15:25:17 بحسب Nasdaq GlobeNewswire

Scilex Holding Company Announces $10 Million Bought Deal Offering

29 فبراير 2024 17:32:38 بحسب Nasdaq GlobeNewswire

Scilex Holding Company Announces Major Initiative with a Leading National Pharmacy Chain to Stock GLOPERBA® in Most of Their Stores Throughout the U.S.

28 فبراير 2024 09:00:00 بحسب Nasdaq GlobeNewswire

Scilex Holding Company Announces Acceptance of Abstract for Poster and Oral Presentation at the Annual Meeting of the American Academy of Pain Medicine (AAPM)

27 فبراير 2024 09:00:00 بحسب Nasdaq GlobeNewswire

Scilex Holding Company’s Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Enters into a Term Sheet with Virpax Pharmaceuticals, Inc. Regarding a Mutual Release and Settlement Agreement

26 فبراير 2024 16:53:22 بحسب Nasdaq GlobeNewswire

Scilex Holding Company Announces that ZTlido® Achieves a Major Milestone - Over One Million Patients Treated Since its Launch - and Two Additional Milestones Met

26 فبراير 2024 09:00:00 بحسب Nasdaq GlobeNewswire

Scilex Holding Company Announces Publication in Anesthesiology Journal of Results from an Investigator-Initiated Research Study Using ZTlido® for the Treatment of Chronic Neck Pain¹

20 فبراير 2024 09:00:00 بحسب Nasdaq GlobeNewswire

Scilex Holding Company Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2023 Accomplishments and Outlook for 2024

08 يناير 2024 09:00:00 بحسب Nasdaq GlobeNewswire

Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The Fiscal Year Ended December 31, 2023, Based On Currently Available Information

02 يناير 2024 09:00:00 بحسب Nasdaq GlobeNewswire

Scilex Holding Company Announces Filing of a New Drug Submission (NDS) to Health Canada’s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in Canada

26 ديسمبر 2023 11:00:00 بحسب Nasdaq GlobeNewswire

Scilex Holding Company Announces that According to Prescription Data from Symphony Health, ZTlido® is the Most Prescribed Non-Opioid Branded Pain Treatment By Pain Specialists

20 ديسمبر 2023 09:00:00 بحسب Nasdaq GlobeNewswire

Scilex Holding Company Announces Results from Market Research with Rheumatologists Reveal a High Degree of Interest in Gloperba® as a Liquid Colchicine Formulation Designed for Precision Dosing

19 ديسمبر 2023 09:00:00 بحسب Nasdaq GlobeNewswire

Scilex Holding Company announces major pharmacy initiative with the national leading pharmacy chain to stock ELYXYB® in most of their stores throughout the U.S.

15 ديسمبر 2023 09:00:00 بحسب Nasdaq GlobeNewswire

Scilex Holding Company Announces Expanded Access to ELYXYB® By the Execution of First ELYXYB® Insurance Coverage Agreement with One of the Top Three National PBMs (Pharmacy Benefit Manager) for its Medicare Population

12 ديسمبر 2023 09:00:00 بحسب Nasdaq GlobeNewswire

Scilex Holding Company announces that ZTlido® (lidocaine topical system) will be added as a preferred agent to the Medicaid Preferred Drug List (PDL) in two new states: one Midwestern and one Southern State

06 ديسمبر 2023 09:00:00 بحسب Nasdaq GlobeNewswire

Scilex Holding Company announces the addition of ZTlido® (lidocaine topical system) as a preferred agent to the Medicaid Preferred Drug List (PDL) of the State of Tennessee

04 ديسمبر 2023 09:00:00 بحسب Nasdaq GlobeNewswire

Scilex Holding Company Generates Monthly Revenue In November 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The One Month Ended November 2023, And Year-To-Date Through November 30, 2023, Based On Currently Available Information

01 ديسمبر 2023 09:00:00 بحسب Nasdaq GlobeNewswire